


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-19 (canceled)

20 (currently amended) A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound or salt of claim 1 to the animal of the formula (I):



(I)

wherein: X is $-\text{CHR}_5-$, $-\text{CHR}_5\text{-alkyl-}$, or $-\text{CHR}_5\text{-alkenyl-}$;

R₁ is selected from the group consisting of:

$-\text{R}_4-\text{NR}_3-\text{SO}_2-\text{R}_6\text{-alkyl-}$;

$-\text{R}_4-\text{NR}_3-\text{SO}_2-\text{R}_6\text{-alkenyl-}$;

$-\text{R}_4-\text{NR}_3-\text{SO}_2-\text{R}_6\text{-aryl-}$;

$-\text{R}_4-\text{NR}_3-\text{SO}_2-\text{R}_6\text{-heteroaryl-}$;

$-\text{R}_4-\text{NR}_3-\text{SO}_2-\text{R}_6\text{-heterocyclyl-}$;

$-\text{R}_4-\text{NR}_3-\text{SO}_2-\text{R}_7$;

$-\text{R}_4-\text{NR}_3-\text{SO}_2-\text{NR}_5-\text{R}_6\text{-alkyl-}$;

$-\text{R}_4-\text{NR}_3-\text{SO}_2-\text{NR}_5-\text{R}_6\text{-alkenyl-}$;

$-\text{R}_4-\text{NR}_3-\text{SO}_2-\text{NR}_5-\text{R}_6\text{-aryl-}$;

$-\text{R}_4-\text{NR}_3-\text{SO}_2-\text{NR}_5-\text{R}_6\text{-heteroaryl-}$;

$-\text{R}_4-\text{NR}_3-\text{SO}_2-\text{NR}_5-\text{R}_6\text{-heterocyclyl-}$; and

-R₄-NR₃-SO₂-NH₂;

R₂ is selected from the group consisting of:

-hydrogen;

-alkyl;

-alkenyl;

-aryl;

-heteroaryl;

-heterocyclyl;

-alkyl-Y-alkyl;

-alkyl-Y-alkenyl;

-alkyl-Y-aryl; and

-alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;

-halogen;

-N(R₅)₂;

-CO-N(R₅)₂;

-CO-C₁₋₁₀ alkyl;

-CO-O-C₁₋₁₀ alkyl;

-N₃;

-aryl;

-heteroaryl;

-heterocyclyl;

-CO-aryl; and

-CO-heteroaryl;

Y is -O- or -S(O)₀₋₂;

R₃ is H, C₁₋₁₀ alkyl, or arylalkyl;

R₄ is alkyl or alkenyl, which may be interrupted by one or more -O- groups; or when R₃ is C₁₋₁₀ alkyl R₃ and R₄ can join together to form a piperidine-ring;

each R₅ is independently H, C₁₋₁₀ alkyl, or C₂₋₁₀ alkenyl;

R₆ is a bond, alkyl, or alkenyl, which may be interrupted by one or more

-O- groups;

R₇ is C₁₋₁₀ alkyl; or when R₃ is C₁₋₁₀ alkyl R₃ and R₇ can join together to form a 5-membered heterocyclic ring;

n is 0; and


each R present is independently selected from the group consisting of C₁₋₁₀ alkyl,

C₁₋₁₀ alkoxy, hydroxy, halogen and trifluoromethyl;

or a pharmaceutically acceptable salt thereof, that induces cytokine biosynthesis.

21-25 (canceled)

26 (currently amended) A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound or salt of claim 13 to the animal of the formula (II):



(II)

wherein: X is -CHR₅-, -CHR₅-alkyl-, or -CHR₅-alkenyl-;

R₁ is selected from the group consisting of:

-R₄-NR₃-SO₂-R₆-alkyl;

-R₄-NR₃-SO₂-R₆-alkenyl;

-R₄-NR₃-SO₂-R₆-aryl;

-R₄-NR₃-SO₂-R₆-heteroaryl;

-R₄-NR₃-SO₂-R₆-heterocyclyl;

-R₄-NR₃-SO₂-R₇;

-R₄-NR₃-SO₂-NR₅-R₆-alkyl;

-R₄-NR₃-SO₂-NR₅-R₆-alkenyl;

-R₄-NR₃-SO₂-NR₅-R₆-aryl;

-R₄-NR₃-SO₂-NR₅-R₆-heteroaryl;

-R₄-NR₃-SO₂-NR₅-R₆-heterocyclyl; and

-R₄-NR₃-SO₂-NH₂;

R₂ is selected from the group consisting of:

-hydrogen;

-alkyl;

-alkenyl;

-aryl;

-heteroaryl;

-heterocyclyl;

-alkyl-Y-alkyl;

-alkyl-Y-alkenyl;

-alkyl-Y-aryl; and

-alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;

-halogen;

-N(R₅)₂;

-CO-N(R₅)₂;

-CO-C₁₋₁₀ alkyl;

-CO-O-C₁₋₁₀ alkyl;

-N₃;

-aryl;

-heteroaryl;

-heterocyclyl;

-CO-aryl; and

-CO-heteroaryl;

Y is -O- or -S(O)₀₋₂;

R₃ is H, C₁₋₁₀ alkyl, or arylalkyl;

R₄ is alkyl or alkenyl, which may be interrupted by one or more -O- groups; or
when R₃ is C₁₋₁₀ alkyl R₃ and R₄ can join together to form a piperidine ring;
each R₅ is independently H, C₁₋₁₀ alkyl, or C₂₋₁₀ alkenyl;
R₆ is a bond, alkyl, or alkenyl, which may be interrupted by one or more
-O- groups;
R₇ is C₁₋₁₀ alkyl; or when R₃ is C₁₋₁₀ alkyl R₃ and R₇ can join together to form a 5-
membered heterocyclic ring;
n is 0 to 4; and
each R present is independently selected from the group consisting of C₁₋₁₀ alkyl,
C₁₋₁₀ alkoxy, hydroxy, halogen, and trifluoromethyl;
or a pharmaceutically acceptable salt thereof, that induces cytokine biosynthesis.

27 (new) A method of inducing cytokine biosynthesis in an animal comprising administering a compound selected from the group consisting of

N-(2-{2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]ethoxy}ethyl)-*N*-methylpropane-2-sulfonamide;

N-{2-[2-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)ethoxy]ethyl}methanesulfonamide;

N-(2-[2-(4-amino-2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)ethoxy]ethyl}methanesulfonamide; and

N-(2-[2-(4-amino-2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)ethoxy]ethyl}propane-2-sulfonamide;

or a pharmaceutically acceptable salt thereof, to the animal in an amount effective for cytokine induction.

28 (new) A method of treating a viral disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound selected from the group consisting of

N-(2-{2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]ethoxy}ethyl)-*N*-methylpropane-2-sulfonamide;

N-{2-[2-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)ethoxy]ethyl}methanesulfonamide;

N-{2-[2-(4-amino-2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)ethoxy]ethyl}methanesulfonamide; and

N-{2-[2-(4-amino-2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)ethoxy]ethyl}propane-2-sulfonamide;

or a pharmaceutically acceptable salt thereof, that induces cytokine biosynthesis.

29 (new) A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound selected from the group consisting of

N-(2-{2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]ethoxy}ethyl)-*N*-methylpropane-2-sulfonamide;

N-{2-[2-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)ethoxy]ethyl}methanesulfonamide;

N-{2-[2-(4-amino-2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)ethoxy]ethyl}methanesulfonamide; and

N-{2-[2-(4-amino-2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)ethoxy]ethyl}propane-2-sulfonamide;

or a pharmaceutically acceptable salt thereof, that induces cytokine biosynthesis.